These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 8181862

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD.
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S.
    J Immunol; 2001 Dec 01; 167(11):6669-77. PubMed ID: 11714839
    [Abstract] [Full Text] [Related]

  • 26. Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide.
    Mescher MF, Rogers JD.
    J Immunother Emphasis Tumor Immunol; 1996 Mar 01; 19(2):102-12. PubMed ID: 8732693
    [Abstract] [Full Text] [Related]

  • 27. Eradication of established tumors by CD8+ T cell adoptive immunotherapy.
    Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM.
    Immunity; 2000 Aug 01; 13(2):265-76. PubMed ID: 10981969
    [Abstract] [Full Text] [Related]

  • 28. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H, Horvath C, Lurquin C, Cerottini JC, MacDonald HR.
    J Immunol; 1998 Jun 01; 160(11):5522-9. PubMed ID: 9605156
    [Abstract] [Full Text] [Related]

  • 29. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
    Chou T, Chang AE, Shu SY.
    J Immunol; 1988 Apr 01; 140(7):2453-61. PubMed ID: 2450925
    [Abstract] [Full Text] [Related]

  • 30. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA, Roest PA, Becker MJ, Weimar IS, Dullens HF, Den Otter W.
    Immunobiology; 1992 Nov 01; 186(3-4):214-29. PubMed ID: 1490728
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.
    Adris S, Chuluyan E, Bravo A, Berenstein M, Klein S, Jasnis M, Carbone C, Chernajovsky Y, Podhajcer OL.
    Cancer Res; 2000 Dec 01; 60(23):6696-703. PubMed ID: 11118055
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM, Winter H, Urba WJ, Fox BA.
    J Immunol; 2000 Oct 15; 165(8):4246-53. PubMed ID: 11035058
    [Abstract] [Full Text] [Related]

  • 37. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.
    Becker C, Pohla H, Frankenberger B, Schüler T, Assenmacher M, Schendel DJ, Blankenstein T.
    Nat Med; 2001 Oct 15; 7(10):1159-62. PubMed ID: 11590442
    [Abstract] [Full Text] [Related]

  • 38. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A, Aruga E, Cameron MJ, Chang AE.
    J Leukoc Biol; 1997 Apr 15; 61(4):507-16. PubMed ID: 9103238
    [Abstract] [Full Text] [Related]

  • 39. Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells.
    Williams BA, Makrigiannis AP, Blay J, Hoskin DW.
    Int J Cancer; 1997 Nov 04; 73(3):416-23. PubMed ID: 9359490
    [Abstract] [Full Text] [Related]

  • 40. Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells.
    Kjaergaard J, Peng L, Cohen PA, Shu S.
    Clin Immunol; 2003 Jul 04; 108(1):8-20. PubMed ID: 12865066
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.